ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

SRPT Sarepta Therapeutics Inc New

127.50
-1.30 (-1.01%)
After Hours
Last Updated: 23:07:58
Delayed by 15 minutes
Share Name Share Symbol Market Type
Sarepta Therapeutics Inc New NASDAQ:SRPT NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -1.30 -1.01% 127.50 125.75 127.50 129.70 126.53 128.65 1,092,772 23:07:58

Sarepta Therapeutics to Present at the Morgan Stanley 17th Annual Global Healthcare Conference

03/09/2019 9:30pm

GlobeNewswire Inc.


Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Sarepta Therapeutics Charts.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present at the Morgan Stanley 17th Annual Global Healthcare Conference on Monday, September 9, 2019 at 11:05 a.m. ET. The fireside chat will be held at the Grand Hyatt New York in New York City, NY.

The presentation will be webcast live under the investor relations section of Sarepta’s website at www.sarepta.com and will be archived there following the presentation for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Sarepta TherapeuticsSarepta is at the forefront of precision genetic medicine, having built an impressive and competitive position in Duchenne muscular dystrophy (DMD) and more recently in gene therapies for 6 Limb-girdle muscular dystrophy diseases (LGMD), Charcot-Marie-Tooth (CMT), MPS IIIA, Pompe and other CNS-related disorders, totaling over 20 therapies in various stages of development. The Company’s programs and research focus span several therapeutic modalities, including RNA, gene therapy and gene editing. Sarepta is fueled by an audacious but important mission: to profoundly improve and extend the lives of patients with rare genetic-based diseases. For more information, please visit www.sarepta.com.

Internet Posting of Information

We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us. 

Source: Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc.Investors: Ian Estepan, 617-274-4052 iestepan@sarepta.com

Media:Tracy Sorrentino, 617-301-8566tsorrentino@sarepta.com

1 Year Sarepta Therapeutics Chart

1 Year Sarepta Therapeutics Chart

1 Month Sarepta Therapeutics Chart

1 Month Sarepta Therapeutics Chart

Your Recent History

Delayed Upgrade Clock